The mission of the Center for Renal Diseases is to diagnose and prevent kidney disease, anticipate complications, and treat renal problems before they become life threatening. The center is staffed with experienced nephrologists and other healthcare professionals who develop and implement customized treatment for polycystic kidney disease (PKD), kidney stones, glomerulonephritis (GN), and the Anemia Clinic.
Polycystic Kidney Disease Clinic (PKD)»
The PKD Clinic uses a comprehensive medical evaluation including genetic testing and counseling, imaging of the kidneys and associated organs, and a treatment program designed by an experienced nephrologist.
- Expanded clinical services, including diet and fluid management, monitoring by trained nurses and regular evaluations by committed nephrologists.
- Specialized services for surgical management of PKD complications.
- Support from experienced pediatric nephrologists.
- A basic research team that works in areas relevant to PKD, such as cell signaling pathways that effect cell growth, experimental work in biological models of PKD and kidney tissue studies.
- The PKD Clinic is engaged in important national PKD research studies.
- The center is actively building its PKD registry, which will serve as a valuable foundation for a comprehensive PKD Clinic.
Kidney Stone Clinic»
Nephrologists and urologists who specialize in kidney stones evaluate patients together to provide a comprehensive approach to diagnosis and management. Experts identify causes of stone formation in order to prevent new stones from forming. Physicians use a combination of blood tests, stone analysis, and 24-hour urine collection to determine the cause for kidney stone formation. Patients leave with a better understanding of why kidney stones develop and what changes they can make in their everyday lives to prevent them.
- An effort with the Glickman Urological & Kidney Institute provides patients with accessible, comprehensive treatment. The center offers complete kidney stone management from surgical solutions to preventive strategies.
- A systematic approach to kidney stone management involves rigorous patient education so individuals can take an active role in prevention.
- The Kidney Stone Clinic partners with other Cleveland Clinic departments to evaluate and treat individuals who are predisposed to kidney stones, such as patients with gastrointestinal disorders, metabolic disorders and bariatric patients.
The Glomerulonephritis Board is a medical board composed of world recognized nephrologists, rheumatologists, immunologists, renal pathologists and other interested physicians whom review complex nephrological glomerulonephritis cases.
- Individual patient cases are presented to the medical board for diagnosis, and treatment recommendations based on the clinical history, laboratory work, and kidney biopsy.
- The most current evidence based medicine is used in recommending management and treatment strategies.
- Patients benefit by having leading specialists discuss their glomerulonephritis in a multidisciplinary discussion.
- Glomerulonephritis which are discussed, but are not limited to include: lupus nephritis, anti-glomerular basement membrane disease, membranous glomerulonephritis, and focal segmental glomerulosclerosis (FSGS).
- The board participates in National Institutes of Health trials and other impact trials critical to understanding and treating GN.
- Requests for a case review by the GN board can be made by local nephrologists or patients.
More than 1,766 adult native kidney biopsies (not including kidney transplants) have been reviewed at Cleveland Clinic between 2004 and 2011.
Nephrologists at the Cleveland Clinic treat many patients with chronic kidney disease (CKD) who suffer from anemia of chronic kidney disease. Anemia of CKD has been shown to increase fatigue, decrease quality of life, and increase the likelihood of blood transfusions. Treatment requires intravenous administration of iron, B12 injections, and/or other agents to stimulate red blood cell production. The Anemia Clinic, which is staffed by two nurses and a supervising nephrologist, offers a standardized approach to meet individual needs to treat anemia.
Cleveland Clinic is a leader in research to uncover innovative ways of managing PKD with the goal of establishing an evidence-based medical approach to the diagnosis and treatment of the disease.
The Department of Nephrology is a participant in the first national randomized clinical trial of treatments for PKD. The HALT-PKD study involves individuals with autosomal dominant polycystic kidney disease (ADPKD), the most common inherited form of PKD. Participants are given drugs to control hypertension. The study will use kidney growth to measure the effectiveness of an intervention.
This study is important because hypertension complications, including stroke and heart attack, affect many more individuals with ADPKD than with ADPKD-specific conditions, such as liver cysts or brain aneurysms. The goal of this study is to discover methods to slow the progression of ADPKD and related health conditions.
Cleveland Clinic Pilot Study
In addition to the HALT-PKD Trial, a pilot study is under way at Cleveland Clinic to examine the effects of sirolimus in reducing renal cysts and kidney volume in ADPKD patients. Traditionally, sirolimus is an immunosuppressant used in combination with cyclosporine and a steroid medication to prevent the body from rejecting a kidney transplant. The Center for Renal Diseases is at the forefront of research and testing of medications that could change the way PKD is treated in the future.